Short Interest in Ralliant Corporation (NYSE:RAL) Increases By 58.7%

Ralliant Corporation (NYSE:RAL) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 3,747,948 shares, an increase of 58.7% from the January 15th total of 2,361,505 shares. Approximately 3.3% of the shares of the company are short sold. Based on an average daily trading volume, of 1,494,198 shares, the short-interest ratio is currently 2.5 days. Based on an average daily trading volume, of 1,494,198 shares, the short-interest ratio is currently 2.5 days. Approximately 3.3% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

RAL has been the topic of a number of research analyst reports. Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a report on Friday, February 6th. Citigroup reduced their price objective on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Weiss Ratings cut shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a research note on Thursday, February 5th. Royal Bank Of Canada dropped their target price on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 6th. Finally, Truist Financial reduced their target price on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $50.50.

Insiders Place Their Bets

In other Ralliant news, SVP Amir A. Kazmi bought 2,545 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were purchased at an average cost of $39.27 per share, for a total transaction of $99,942.15. Following the transaction, the senior vice president directly owned 39,699 shares in the company, valued at $1,558,979.73. The trade was a 6.85% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin E. Bryant purchased 1,250 shares of Ralliant stock in a transaction on Friday, February 6th. The shares were acquired at an average price of $39.97 per share, with a total value of $49,962.50. Following the transaction, the director directly owned 4,653 shares in the company, valued at $185,980.41. This trade represents a 36.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 8,145 shares of company stock valued at $332,233.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of RAL. Allworth Financial LP lifted its holdings in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the last quarter. Rothschild Investment LLC lifted its stake in Ralliant by 98.1% in the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares during the last quarter. Keybank National Association OH lifted its stake in Ralliant by 1.6% in the fourth quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock valued at $1,001,000 after acquiring an additional 305 shares during the last quarter. UMB Bank n.a. grew its position in Ralliant by 49.6% in the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock worth $50,000 after acquiring an additional 326 shares in the last quarter. Finally, SouthState Bank Corp increased its stake in shares of Ralliant by 48.2% during the 4th quarter. SouthState Bank Corp now owns 1,052 shares of the company’s stock worth $54,000 after purchasing an additional 342 shares during the last quarter.

Ralliant Trading Up 3.4%

RAL stock traded up $1.43 during mid-day trading on Monday, reaching $44.03. 2,283,937 shares of the stock traded hands, compared to its average volume of 2,574,496. Ralliant has a 52-week low of $37.27 and a 52-week high of $57.02. The stock’s fifty day moving average is $50.79 and its 200-day moving average is $46.56. The company has a market cap of $4.97 billion and a P/E ratio of 22.46. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. Ralliant’s dividend payout ratio is presently 10.20%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.